Aster DM Quality Care Limited (ASTERDM): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Aster DM Quality Care Limited, explained in plain English.
- Aster DM Quality Care Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- ASTERDM closed at ₹741.75 on 18 November 2026.
- Over the past year the shares are up 9.2%, trading between ₹519.10 and ₹891.30.
- Our Pulse grade checklist scores it D (36/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 29.37% with a maximum drawdown of -25.87% and a beta of 0.41 against NIFTY 50.
- Recent coverage: Aster DM Quality Care Q2 net profit more than doubles to ₹262 crore
- Recent coverage: Kotak adds 5 new midcap stocks which fell up to 16% in one month to its model portfolio. Take a look
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aurobindo Pharma, Biocon
Figures from the current session. Market open.
Pharma & Healthcare · Medical Care Facilities
Aster DM Quality Care Limited (ASTERDM)
₹737.95
▼ 12.05 (-1.61%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Strong momentum · 4/51M
+9.43%
3M
-9.98%
6M
-2.08%
1Y
+8.67%
Where it sits in its 52-week range
60%Below 52-week high
15.1%
37.2% above the low
Momentum read
Strong
4/5 checks passed
52-wk high
₹869.7
52-wk low
₹537.95
Market cap
₹64,251 Cr
P/E (trailing)
93.9
Dividend yield
—
ROE
8.05%
Profit margin
7.23%
Revenue growth
136.3%
Price / Book
7.78
Debt / Equity
64.36
EPS (TTM)
7.86
Book value
₹94.84
Beta
0.41
Pulse grade: C, 56 out of 100
Momentum
B- ✓Trading above 50-day average
- ✓Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✕Positive 3-month return
Growth
A- ✓Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✓Quarterly profits trending up
Profitability
F- ✕Return on equity above Pharma & Healthcare median (14.56%)
- ✕Return on equity above 12%
- ✕Profit margin above Pharma & Healthcare median (13.82%)
Safety
D- ✕Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹2,829 crore · net profit ₹262 crore · margin 9.3%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
ASTERDM headlines
No ASTERDM stories right now.
ASTERDM filings & announcements
ASTERDM, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
29.37%
Sharpe ratio
0.3
Sortino ratio
0.44
Max drawdown
-25.87%
Daily VaR (95%)
-2.74%
CAGR (1Y)
11.42%
Return skew
0.23
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.